Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS) - Summary - MDSpire
Advertisement
Association of blood-based neurodegenerative biomarkers with cognitive functioning and dementia in India (LASI-DAD) and the United States (HRS)
To examine associations between blood-based neurodegenerative biomarkers and cognitive functioning in older adults from India and the United States, highlighting comparative insights.
Key Findings:
Higher levels of GFAP and NfL were associated with worse cognitive function and increased likelihood of dementia in both populations, indicating their potential as universal markers.
GFAP and NfL were linked to cognitive decline in HRS but not in LASI-DAD, suggesting population-specific factors.
Higher Aβ42/Aβ40 ratio correlated with worse cognitive functioning and more dementia in HRS, while it was associated with better cognitive functioning in LASI-DAD, highlighting the need for contextual interpretation.
pTau181 showed no significant association with cognitive functioning in either country, indicating its limited utility in these populations.
Interpretation:
The study highlights the potential of blood-based neurodegenerative biomarkers in predicting cognitive decline and dementia, with varying associations observed between populations in India and the U.S., emphasizing the need for tailored approaches.
Limitations:
Differences in environmental, social, and economic factors between India and the U.S. may influence biomarker levels and cognitive outcomes, potentially skewing results.
The study's cross-sectional design limits causal inferences, necessitating further longitudinal studies.
Conclusion:
Blood-based biomarkers may serve as valuable tools for early detection of cognitive impairment and dementia across diverse populations, though their utility may vary by context, necessitating careful interpretation.
by Jung Ki Kim, Masroor Anwar, Abhishek Gupta, Bharat Thyagarajan, Peifeng Hu, Jessica D Faul, David R Weir, Kenneth M Langa, Jinkook Lee, Sharmistha Dey, Eileen M Crimmins
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
